A Review on the Interconnection Between Drug Design and Controlled Drug Delivery Systems

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2026 | Volume : 3 | 01 | Page :
    By

    Mohd. Wasiullah,

  • Piyush Yadav,

  • Amit Pal,

  1. Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
  2. Head, Department of Pharma: Chemistry, Prasad Institute of Technology, Jaunpur,Uttar Pradesh, India
  3. Scholar, Department of Pharmacy, Prasad institute of Technology, Jaunpur,Uttar Pradesh, India

Abstract

Drug discovery and delivery are two branches of science that have historically developed as independent areas of discovery – one focused on optimizing the properties of molecules for biological activity, and the other on controlling the rate, site, and duration for drug release. However, in contemporary pharmacy, these two areas have merged into a single integrated approach – where drug discovery and delivery strategies co-influence each other at each point of the development process. Rational drug design now considers pharmacokinetic and pharmacodynamic aspects dictated by delivery platforms, while sophisticated controlled drug delivery systems (CDDS) are developed with molecular characteristics in mind, with the goal of optimizing drug action. The purpose of this review is to highlight the relationship between drug design and CDDS, including the main principles and innovations that span the technology, molecular modeling, nanotechnology, and translational aspects that have accompanied the drug design and CDDS relationship. A primary focus is on how the relationship drug design, and CDDS advances toward more precision therapeutics, lowers systemic toxicity, and improves patient compliance. Finally, the state-of-the-art is assessed in terms of the practicality of computational design, more personalized delivery, and adaptive materials toward the drug design and delivery industries as a means of drug innovation.

Keywords: ADMET, artificial intelligence, controlled drug delivery, drug design, molecular modeling, nanotechnology

How to cite this article:
Mohd. Wasiullah, Piyush Yadav, Amit Pal. A Review on the Interconnection Between Drug Design and Controlled Drug Delivery Systems. Emerging Trends in Personalized Medicines. 2026; 03(01):-.
How to cite this URL:
Mohd. Wasiullah, Piyush Yadav, Amit Pal. A Review on the Interconnection Between Drug Design and Controlled Drug Delivery Systems. Emerging Trends in Personalized Medicines. 2026; 03(01):-. Available from: https://journals.stmjournals.com/etpm/article=2026/view=238563


References

  1. Langer Drug delivery and targeting. Nature. 1998;392(Suppl 6679):5–10. doi: 10.1038/32113.
  2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings: The rule of Adv Drug Deliv Rev. 2001;46(1–3):3–26. doi: 10.1016/S0169-409X(00)00129-0.
  3. Siepmann J, Peppas Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48(2–3):139–157. doi: 10.1016/S0169- 409X(01)00112-0.
  4. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science. 2004;303(5665):1818–1822. doi: 10.1126/science.1095833.
  5. Langer R, Peppas Advances in biomaterials, drug delivery, and bionanotechnology. AIChE J. 2003;49(12):2990–3006. doi: 10.1002/aic.690491202.
  6. Batool M, Ahmad B, Choi S. A structure-based drug discovery paradigm. Int J Mol Sci. 2019;20(6):1383. doi: 10.3390/ijms20061383.
  7. Ferreira LG, dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015;20(7):13384–13421. doi: 10.3390/molecules200713384.
  8. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124. doi: 1038/s41573-020-0090-8.
  9. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MP, Acosta-Torres LS, et Nano- based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71. doi: 10.1186/s12951-018-0392-8.
  10. Torchilin Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813–827. doi: 10.1038/nrd4333.
  11. Zhang Y, Chan HF, Leong Advanced materials and processing for drug delivery: The interface of design and delivery. Adv Drug Deliv Rev. 2013;65(5):791–792. doi: 10.1016/j.addr.2013.03.001.
  12. Dutta D, et al. Integration of artificial intelligence in drug discovery and development: Trends and perspectives. Trends Pharmacol Sci. 2023;44(7):566–580. doi: 10.1016/j.tips.2023.04.004.
  13. Patra PA, et al. Nanomedicine: Past, present, and future—a global perspective. J Control Release. 2015;205:1–13. doi: 10.1016/j.jconrel.2015.02.039.
  14. Yusuf A, et al. Nanoparticles as drug delivery systems: A review of the state-of-the-art and future directions. Polymers (Basel). 2023;15(7):1596. doi: 10.3390/polym15071596.
  15. Siepmann J, Goepferich Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev. 2001;48(2–3):229–247. doi: 10.1016/S0169-409X(01)00116-8.
  16. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25–35. doi: 10.1016/0378-5173(83)90064-9.
  17. Vlieghe P, Khrestchatisky M. Prodrug approach in modern drug design: Strategies and examples. Med Res Rev. 2013;33(2):1–28. doi: 10.1002/med.21245.
  18. Abet V, et Prodrug approach: An overview of recent cases (2004–2016). Eur J Med Chem. 2017;127:810–827. doi: 10.1016/j.ejmech.2016.10.061.
  19. Najjar A, et The prodrug approach in the era of drug design. Drug Des Devel Ther. 2019;13:1–
  20. doi: 10.2147/DDDT.S176450.
  21. N’Da Prodrug strategies for enhancing percutaneous and transdermal delivery. Molecules.

2014;19(12):20780–20816. doi: 10.3390/molecules191220780.

  1. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, et Drug delivery systems: An updated review. Pharmaceutics. 2012;4(1):1–19. doi: 10.3390/pharmaceutics4010001.
  2. Zhang R, et al. Smart polymers for controlled release: Progress and prospects. Prog Polym Sci. 2021;116:101386. doi: 10.1016/j.progpolymsci.2021.101386.
  3. Jahangirian H, et A review of drug delivery systems based on nanotechnology and green chemistry. Int J Nanomedicine. 2017;12:5577–5593. doi: 10.2147/IJN.S132838.
  4. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery. Adv Drug Deliv Rev. 2011;63(3):136–151. doi: 10.1016/j.addr.2010.04.009.
  5. Kakkar A, et al. Designing nanomedicines for clinical Nat Rev Chem. 2022;6(8):566–
  6. doi: 10.1038/s41570-022-00401-9.
  7. Doxsee CL, et al. Antibody–drug conjugates: Design, development, and delivery considerations. Nat Rev Drug Discov. 2020;19(11):763–780. doi: 10.1038/s41573-020-00043-3.
  8. Boiani M, González Imidazole and benzimidazole derivatives: Chemotherapeutic design considerations. Mini Rev Med Chem. 2005;5(4):409–424. doi: 10.2174/1389557053765513.
  9. Mitchell MJ, et Engineering nanoparticles for precision medicine and overcoming drug delivery barriers. Nat Rev Drug Discov. 2021;20(2):101–124. doi: 10.1038/s41573-020-0090-8.
Ahead of Print Subscription Review Article
Volume 03
01
Received 23/12/2025
Accepted 22/01/2026
Published 31/01/2026
Publication Time 39 Days
48

Login


My IP

PlumX Metrics